PREVENTIVE AND CURATIVE ASPECTS OF AYURVEDA IN LIFESTYLE DISORDERS

Ayurveda has two objects: preservation of the health in the healthy and treatment of disorders in the diseased. The multidimensional role of Ayurveda is clear from the title. In present Era, over stress and bad food habits or bad Life style reduces individual happiness and predispose to many disease e.g. dyslipidemia, obesity, cardio vascular disease, diabetes mellitus, hypertension and other clinical conditions. Ayurveda system is for complete well being of an individual. With the changing demand and awareness among people these days, the role of ancient health care systems like Ayurveda is an emerging reality. Shodhana, Shamana & Rasayana therapy along with compliances of Dinacharya, Ritucharya as mentioned In classical Ayurveda texts etc play an important role in promoting the health and prolonging the Life span by establishing homeostasis between Dosha, Dhatu & Mala. It helps to keep diseases free at bay. Ayurveda System of medicine is holistic and free from side effects. Preventive aspect of this system are shown in various dos and don'ts in Dinacharya, Ritucharya, Sadvirtta, Rasayana and Sanshodhana therapy etc. The curative aspect and various drug formulations or regimens has been given described specially in description of the management of various diseases. The role of the Ayurveda in prevention and cure of life style disorders will be explained in full paper

Association of respiratory symptoms and lung function with occupation in the multinational Burden of Obstructive Lung Disease (BOLD) study

Background Chronic obstructive pulmonary disease has been associated with exposures in the workplace. We aimed to assess the association of respiratory symptoms and lung function with occupation in the Burden of Obstructive Lung Disease study. Methods We analysed cross-sectional data from 28 823 adults (≥40 years) in 34 countries. We considered 11 occupations and grouped them by likelihood of exposure to organic dusts, inorganic dusts and fumes. The association of chronic cough, chronic phlegm, wheeze, dyspnoea, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)/FVC with occupation was assessed, per study site, using multivariable regression. These estimates were then meta-analysed. Sensitivity analyses explored differences between sexes and gross national income. Results Overall, working in settings with potentially high exposure to dusts or fumes was associated with respiratory symptoms but not lung function differences. The most common occupation was farming. Compared to people not working in any of the 11 considered occupations, those who were farmers for ≥20 years were more likely to have chronic cough (OR 1.52, 95% CI 1.19–1.94), wheeze (OR 1.37, 95% CI 1.16–1.63) and dyspnoea (OR 1.83, 95% CI 1.53–2.20), but not lower FVC (β=0.02 L, 95% CI −0.02–0.06 L) or lower FEV1/FVC (β=0.04%, 95% CI −0.49–0.58%). Some findings differed by sex and gross national income. Conclusion At a population level, the occupational exposures considered in this study do not appear to be major determinants of differences in lung function, although they are associated with more respiratory symptoms. Because not all work settings were included in this study, respiratory surveillance should still be encouraged among high-risk dusty and fume job workers, especially in low- and middle-income countries.publishedVersio

Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study

The Burden of Obstructive Lung Disease (BOLD) study was established to assess the prevalence of chronic airflow obstruction, a key characteristic of chronic obstructive pulmonary disease, and its risk factors in adults (≥40 years) from general populations across the world. The baseline study was conducted between 2003 and 2016, in 41 sites across Africa, Asia, Europe, North America, the Caribbean and Oceania, and collected high-quality pre- and post-bronchodilator spirometry from 28 828 participants. The follow-up study was conducted between 2019 and 2021, in 18 sites across Africa, Asia, Europe and the Caribbean. At baseline, there were in these sites 12 502 participants with high-quality spirometry. A total of 6452 were followed up, with 5936 completing the study core questionnaire. Of these, 4044 also provided high-quality pre- and post-bronchodilator spirometry. On both occasions, the core questionnaire covered information on respiratory symptoms, doctor diagnoses, health care use, medication use and ealth status, as well as potential risk factors. Information on occupation, environmental exposures and diet was also collected

International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS

POTENTIAL INHIBITORS AGAINST SARS-COV-2 BY TARGETING PROTEINS RESPONSIBLE FOR ENVELOPE FORMATION AND VIRION ASSEMBLY

Even though extreme research there is presently no efficient vaccine accessible against the new-found severe acute respiratory syndrome coronavirus-2 causing COVID-19 pandemic. The clinical administration of COVID-19 has been restricted to infection prevention along with control measures linked with supportive care. In the meantime, efforts to achieve a successful therapy to prevent virus replication, alleviate the symptoms, increase survivability as well as reduce mortality are ongoing. In this review, we found that a drug named Tipranavir (used in more than top 20 drugs in different countries against Covid-19) that can be docked against the QNH88662.1 envelope protein [Severe acute respiratory syndrome coronavirus 2] and at least cease the activity so that its action of spreading infection can be prevented. Pharmacokinetics and ADME studies show that drugs need some improvement. It is slightly heavier than Lipinski rule of five criteria. We propose improvement in future aspects

Elements of Life

30-34Depending on their varied function and requirements, elements have been categorised as essential, non-essential and toxic elements

Efficacy and safety of recombinant thrombomodulin for the prophylaxis of veno-occlusive complication in allogeneiccit hematopoietic stem cell transplantation: A systematic review and meta-analysis

Background: Hepatic veno-occlusive disease (VOD), also termed as sinusoidal obstruction syndrome (SOS), is a lethal complication after hematopoietic stem cell transplantation (HSCT). Various factors put patients undergoing allogeneic HSCT at an increased risk for VOD. Thrombomodulin (TM) is an important factor which has a wide range of effects, including anticoagulant, anti-inflammatory, angiogenic, and protective effect, on endothelial cells. It plays a role in preventing excessive coagulation and thrombosis by binding with thrombin and inhibiting the coagulation cascade. There are a limited number of options for the prevention of this fatal complication. Recombinant thrombomodulin (rTM), an endothelial anticoagulant co-factor, as prophylactic therapy might be able to prevent veno-occlusive complications after stem cell transplantation. Methods: A literature search was performed on PubMed, Embase, and Web of Science. We used the following Mesh terms and Emtree terms, Hepatic Veno-Occlusive Diseases OR Sinusoidal Obstruction OR Stem Cell Transplantations AND Thrombomodulin from the inception of data up to April 1, 2021. The PICO (Patient/Population, Intervention, Comparison and Outcomes) framework was used for the literature search. Results: For the VOD incidence after HSCTstem cell transplantation, the result was in favor of rTM with a risk ratio (RR) of 0.53 (I2 = 0%, 95% confidence interval [CI] = 0.32-0.89). The incidence of transplant-associated thrombotic microangiopathy (TA-TMA) after HSCT was reduced in rTM group. The RR for incidence of TA-TMA was 0.48 (I2 = 62%, 95% CI = 0.20-1.17) favoring rTM. The RR for incidence of graft-versus-host disease (GvHD) was also lower in rTM group, 0.48 (I2 = 64%, 95% CI = 0.32-0.72). Conclusion: In our meta-analysis, we evaluate the efficacy and safety of rTM in the prevention of SOS after HSCT. According to our results, rTM use led to a significant reduction in SOS episodes, TA-TMA, and GvHD after HSCT